Replies to post #300295 on Avid Bioservices Inc (CDMO)

[shipbuilder]

Yes! BREKKEN

[4OurRetirement]

NiceExosomePost w/Link! WelcomeAboard js18. GltaStockHOLDERS,eom.

[shipbuilder]

It's an animal models and the conclusion still uses the term "suggests". Are the introduced tumors also mouse derived or...? Am I understanding that two if the models are for different types of breast cancer, and the third is pancreatic?

Looking forward to reading the full paper.

[Thomas517]

Okie dokie smokie sounds extremely interesting to me. Sounds extremely positive to me. Sounds like something good little ole pphm is involved in. Who's buying more shares tomorrow? I am. Again. Although on paper I am down a ton a big ton. However one really good pr can change the whole ball game. Just one could make a world of a difference . My hopes my dreams my wishes. Go pphm........

[biopharm]

JS...very nice link re: exosomes and flipped PS

I think John Stafford would approve and like the initials! : )

[asmarterwookie]

Top O' the "ALL FOUR MODELS" Friday Mornin Peregrinners!!!

Thanks and welcome to the board js!!!!!

The 100 penny question is... Does Peregrine have an adequate POC for a strong partnership?

Was more done with Bio Bank Ovarian samples?

Amazing we have a past cheerleader coming back to denounce now.....

PS, it's everywhere cancer and disease are, and its targeted.


Best of Luck and Data!!!!



wook

[ku]

Js, Remember, the following Board members are not going to let their current GIG go. To them, Bavi and exosomes can wait till someone hands them 50 billion which will never happen. Meanwhile they keep collecting :)

Carlton Johnson: $350,000 a year

David Pohl: $290,000 a year

Eric Swartz: $320,000 a year

For sitting in on a few conference calls

[Bamboozler762]

Thanks for the article link JS18, any luck getting access to the full PDF?

Best I've gotten is the unlocked illustrations from HERE (hate how its so close but blurred out). I posted the 3 illustrations and their descriptions below.

(ETA: CJ already posted said link above a few posts below)




Figure 1
Schematic diagram of betabody, KL15C.
Domains 1 and 5 of the plasma PS-binding protein, ß2GP1, were genetically fused to the C-terminus of the CH3 domains of the Fc fragment of human IgG1. A Gly4Ser linker was inserted between the CH3 domains and domains 1 and 5 of ß2GP1. The recombinant betabody was expressed as a dimer





Figure 2
Determination of blood exosomal PS levels for the detection of tumours.
(A) ELISA plates coated with KL15C (PS capture) and duramycin (PE capture) were incubated with the indicated amounts of vesicles containing 50% PS or 50% PE (wt/wt) in PC. After washing, the plates were incubated with biotinylated annexin 5 in the presence of Ca2+ (2 mM) or biotinylated duramycin (no Ca2+) and the amounts of PS or PE captured was quantified with HRP–streptavidin. The amounts of phospholipid indicated on the abscissa represents the assumed amounts of aminophospholipids expressed on the vesicle surface that is available for binding (50% aminophospholipid in PC with half of that in the particles outer leaflet). Closed circles, PS/PC vesicles; open circles, PE/PC vesicles; solid line, annexin 5 detection (PS); dotted line, duramycin detection (PE). (B and C) Human EDTA plasma (100 µl of 50% diluted plasma in PBS) from two confirmed ovarian carcinoma patients (dark grey and light grey) or two sex-matched healthy individuals (diagonal lines and crossed lines) were incubated on ELISA plates coated with (B) KL15C or (C) duramycin. After exosome capture, the plates were developed with both probes as described for the synthetic vesicles in (A). The values shown in (B and C) were calculated from the standard PS and PE curves shown in (A) (PS, left; PE, right) and are the average of two confirmed cancer patients and two healthy individuals.






Figure 3
Detection of PS-expressing tumour-derived exosomes in the blood of tumour-bearing mice.
(A) MDA-MB231 breast cancer model: 8-week-old SCID Balb/c mice were injected orthotopically with 4 × 106 MDA-MB231 cells on day 0. Day 0 blood was taken just before inoculation with tumour cells. The mice were then bled at weekly intervals. Each data point represent 50 µl of pooled plasma from 5 mice. Squares, exposed PE levels on PS-captured exosomes; circles, average tumour volume of the 5 mice. (B) Blood exosome numbers in pooled plasma of mice bearing MDA-MB231 tumours (bars): Aliquots of plasma obtained from animals described in (A) were quantified for total exosome number using the Exocet Exosome Quantification Assay system as described by the manufacturer (Systems Biosciences Inc., Palo Alto, CA, USA). The ratio of PS to particle number (circles) was obtained by dividing the PE values in (A) by the particle count. (C) PYMT breast cancer model: Five FVB PyMT mice were monitored for tumour size and bled weekly for exosome quantification beginning at day 35. Squares, exposed PE levels on PS-captured exosomes; circles, tumour volume. The data represent the average and s.d. for all animals. (D) Student’s t-test P-values for days 35, 42 and 49. Dark grey, PYMT mice; light grey, littermate controls. Individual tumour and exosome plots are shown in Supplementary Figure S5. (E) KIC pancreatic cancer model: Fourteen KIC mice and 14 littermate controls were monitored for body weight and bled weekly for exosome quantification beginning at day 21. Squares, exposed PE levels on PS-captured exosomes; circles, exposed PE levels in littermate control animals. The data represent the average and s.d. for all animals. (F) Student’s t-test P-values for day 21. Dark grey, KIC mice; light grey, KIC control littermates. Individual exosome plots are shown in Supplementary Figure S6A. (G) KPC pancreatic cancer model: Nine KPC mice and 8 littermate controls were monitored for body weight and bled weekly for exosome quantification beginning at day 21. Squares, exposed PE levels on PS-captured exosomes; circles, exposed PE levels in littermate control animals. The data represent the average and s.d. for all animals. (H) Student’s t-test P-values for days 56–84. Dark grey, KPC mice; light grey, KPC control littermates. Individual data sets are shown in Supplementary Figure S7.